{"resourceType":"SubstanceDefinition","id":"mipomersen","identifier":[{"system":"http://example.europa.eu/fhir/SMSId","value":"MIPO78654S"}],"status":{"coding":[{"system":"http://hl7.org/fhir/publication-status","code":"active"}]},"classification":[{"coding":[{"system":"http://example.europa.eu/fhir/SubstanceType","code":"nucleic-acid","display":"Nucleic Acid"}]}],"domain":{"coding":[{"system":"http://example.europa.eu/fhir/Domain","code":"human","display":"Human use"}]},"description":"Mipomersen sodium — a synthetic second-generation 2\u0027-methoxyethyl antisense oligonucleotide that inhibits the molecular target apolipoprotein B-100 (APOB-100). 20-mer phosphorothioate-linked sequence with 2\u0027-MOE wing chemistry.","code":[{"code":{"coding":[{"system":"http://example.europa.eu/fhir/Substance","code":"MIPO78654S"}]}}],"name":[{"name":"Mipomersen Sodium","preferred":true,"language":[{"coding":[{"system":"urn:ietf:bcp:47","code":"en","display":"English"}]}],"official":[{"authority":{"coding":[{"system":"http://hl7.org/fhir/substance-name-authority","code":"INN","display":"INN"}]},"status":{"coding":[{"system":"http://hl7.org/fhir/publication-status","code":"active","display":"Active"}]}}]}],"nucleicAcid":{"sequenceType":{"coding":[{"system":"http://hl7.org/fhir/substance-sequence-type","code":"complete","display":"Complete"}]},"numberOfSubunits":1,"oligoNucleotideType":{"coding":[{"system":"http://hl7.org/fhir/oligo-nucleotide-type","code":"antisense","display":"Antisense oligonucleotide"}]},"subunit":[{"subunit":1,"sequence":"GCCUCAGTCTGCTTCGCACC","length":20,"fivePrime":{"coding":[{"system":"http://hl7.org/fhir/nucleotide-terminus","code":"G","display":"Guanosine"}]},"threePrime":{"coding":[{"system":"http://hl7.org/fhir/nucleotide-terminus","code":"C","display":"Cytidine"}]},"linkage":[{"substance":{"concept":{"coding":[{"system":"http://example.europa.eu/fhir/LinkageSubstance","code":"phosphorothioate","display":"Phosphorothioate linkage"}]}},"residueSite":"1-19"}],"sugar":[{"substance":{"concept":{"coding":[{"system":"http://example.europa.eu/fhir/SugarSubstance","code":"2-MOE","display":"2\u0027-O-(2-methoxyethyl) ribose"}]}},"residueSite":"1-5,16-20"},{"substance":{"concept":{"coding":[{"system":"http://example.europa.eu/fhir/SugarSubstance","code":"deoxyribose","display":"2\u0027-deoxyribose"}]}},"residueSite":"6-15"}]}],"gene":[{"sequenceOrigin":{"coding":[{"system":"http://hl7.org/fhir/gene-sequence-origin","code":"human","display":"Human"}]},"gene":{"concept":{"coding":[{"system":"http://www.genenames.org","code":"APOB","display":"apolipoprotein B"}]}}}]},"relationship":[{"substanceDefinitionCodeableConcept":{"coding":[{"system":"https://www.uniprot.org","code":"P04114","display":"apolipoprotein B-100"}]},"type":{"coding":[{"system":"http://hl7.org/fhir/substance-relationship-type","code":"TherapeuticTarget","display":"Therapeutic target"}]},"interaction":{"coding":[{"system":"http://hl7.org/fhir/substance-interaction-type","code":"inhibition","display":"Inhibition"}]}}]}
{"resourceType":"SubstanceDefinition","id":"example","identifier":[{"system":"http://example.europa.eu/fhir/SMSId","value":"100000099270"}],"status":{"coding":[{"system":"http://example.europa.eu/fhir/Status","code":"200000005004","display":"Current"}]},"classification":[{"coding":[{"system":"http://example.europa.eu/fhir/SubstanceType","code":"100000075670","display":"Chemical"}]}],"domain":{"coding":[{"system":"http://example.europa.eu/fhir/Domain","code":"100000000012","display":"Human use"}]},"code":[{"code":{"coding":[{"system":"http://example.europa.eu/fhir/Substance","code":"SUB99611MIG"}]}}],"name":[{"name":"PARACETAMOL","status":{"coding":[{"system":"http://example.europa.eu/fhir/Status","code":"200000005004","display":"Current"}]},"preferred":true,"language":[{"coding":[{"system":"urn:ietf:bcp:47","code":"en","display":"English"}]}]},{"name":"ПАРАЦЕТАМОЛ","status":{"coding":[{"system":"http://example.europa.eu/fhir/Status","code":"200000005004","display":"Current"}]},"preferred":false,"language":[{"coding":[{"system":"urn:ietf:bcp:47","code":"bg","display":"Bulgarian"}]}]},{"name":"ACETAMINOPHEN","status":{"coding":[{"system":"http://example.europa.eu/fhir/Status","code":"200000005004","display":"Current"}]},"preferred":false,"language":[{"coding":[{"system":"urn:ietf:bcp:47","code":"en","display":"English"}]}]}]}
{"resourceType":"SubstanceDefinition","id":"trastuzumab","identifier":[{"system":"http://example.europa.eu/fhir/SMSId","value":"TRAS9123H"}],"status":{"coding":[{"system":"http://hl7.org/fhir/publication-status","code":"active","display":"Active"}]},"classification":[{"coding":[{"system":"http://example.europa.eu/fhir/SubstanceType","code":"protein","display":"Protein"}]}],"domain":{"coding":[{"system":"http://example.europa.eu/fhir/Domain","code":"human","display":"Human use"}]},"description":"Trastuzumab — humanised IgG1 monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2/ErbB2). Variable regions derived from murine antibody 4D5, grafted onto human IgG1 framework. Produced in Chinese hamster ovary (CHO) cells.","code":[{"code":{"coding":[{"system":"http://example.europa.eu/fhir/Substance","code":"TRAS9123H"}]}}],"name":[{"name":"Trastuzumab","preferred":true,"language":[{"coding":[{"system":"urn:ietf:bcp:47","code":"en","display":"English"}]}],"official":[{"authority":{"coding":[{"system":"http://hl7.org/fhir/substance-name-authority","code":"INN","display":"INN"}]},"status":{"coding":[{"system":"http://hl7.org/fhir/publication-status","code":"active","display":"Active"}]}}]},{"name":"Herceptin","preferred":false}],"protein":{"sequenceType":{"coding":[{"system":"http://hl7.org/fhir/substance-sequence-type","code":"complete","display":"Complete"}]},"numberOfSubunits":2,"disulfideLinkage":["HC22-HC96; HC144-HC200; HC222-LC214; HC228-HC228\u0027; HC231-HC231\u0027; HC265-HC325; HC371-HC429"],"subunit":[{"subunit":1,"sequence":"EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS...","length":450,"nTerminalModification":{"concept":{"coding":[{"system":"http://example.europa.eu/fhir/Modification","code":"pyroglutamate","display":"Pyroglutamic acid (pE)"}]}},"cTerminalModification":{"concept":{"coding":[{"system":"http://example.europa.eu/fhir/Modification","code":"lysine-clipped","display":"C-terminal lysine clipping"}]}}},{"subunit":2,"sequence":"DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK...","length":214}],"gene":[{"sequenceOrigin":{"coding":[{"system":"http://hl7.org/fhir/gene-sequence-origin","code":"humanised-mouse","display":"Humanised mouse"}]},"gene":{"concept":{"coding":[{"system":"http://www.genenames.org","code":"IGHG1","display":"Immunoglobulin heavy constant gamma 1"}]}}}]},"relationship":[{"substanceDefinitionReference":{"reference":"SubstanceDefinition/her2","display":"Receptor tyrosine-protein kinase erbB-2 (HER2)"},"type":{"coding":[{"system":"http://hl7.org/fhir/substance-relationship-type","code":"TherapeuticTarget","display":"Therapeutic target"}]},"interaction":{"coding":[{"system":"http://hl7.org/fhir/substance-interaction-type","code":"binding","display":"Binding"}]},"measurementType":{"coding":[{"system":"http://hl7.org/fhir/substance-measurement-type","code":"kd","display":"Kd"}]},"amountQuantity":{"value":0.1,"unit":"nM","system":"http://unitsofmeasure.org","code":"nmol/L"}}]}
{"resourceType":"SubstanceDefinition","id":"ponatinib-hcl","identifier":[{"system":"http://example.europa.eu/fhir/SMSId","value":"PONA4321C"}],"status":{"coding":[{"system":"http://hl7.org/fhir/publication-status","code":"active","display":"Active"}]},"classification":[{"coding":[{"system":"http://example.europa.eu/fhir/SubstanceType","code":"chemical","display":"Chemical"}]}],"domain":{"coding":[{"system":"http://example.europa.eu/fhir/Domain","code":"human","display":"Human use"}]},"description":"Ponatinib hydrochloride — a small-molecule tyrosine kinase inhibitor (TKI) used in the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Hydrochloride salt of ponatinib.","code":[{"code":{"coding":[{"system":"http://example.europa.eu/fhir/Substance","code":"PONA4321C"}]}}],"name":[{"name":"Ponatinib Hydrochloride","preferred":true,"language":[{"coding":[{"system":"urn:ietf:bcp:47","code":"en","display":"English"}]}],"official":[{"authority":{"coding":[{"system":"http://hl7.org/fhir/substance-name-authority","code":"USAN","display":"USAN"}]},"status":{"coding":[{"system":"http://hl7.org/fhir/publication-status","code":"active","display":"Active"}]}}]}],"molecularWeight":[{"type":{"coding":[{"system":"http://example.europa.eu/fhir/WeightType","code":"exact","display":"Exact"}]},"amount":{"value":569.04,"unit":"g/mol","system":"http://unitsofmeasure.org","code":"g/mol"}}],"moiety":[{"role":{"coding":[{"system":"http://example.europa.eu/fhir/MoietyRole","code":"active-moiety","display":"Active moiety"}]},"name":"Ponatinib","molecularFormula":"C29H27F3N6O"},{"role":{"coding":[{"system":"http://example.europa.eu/fhir/MoietyRole","code":"counter-ion","display":"Counter-ion (salt)"}]},"name":"Hydrochloride","molecularFormula":"HCl"}],"relationship":[{"substanceDefinitionCodeableConcept":{"coding":[{"system":"https://www.uniprot.org","code":"A9UF07","display":"BCR-ABL1 fusion kinase"}]},"type":{"coding":[{"system":"http://hl7.org/fhir/substance-relationship-type","code":"TherapeuticTarget","display":"Therapeutic target"}]},"interaction":{"coding":[{"system":"http://hl7.org/fhir/substance-interaction-type","code":"inhibition","display":"Inhibition"}]},"measurementType":{"coding":[{"system":"http://hl7.org/fhir/substance-measurement-type","code":"ic50","display":"IC50"}]},"amountQuantity":{"value":0.37,"unit":"nM","system":"http://unitsofmeasure.org","code":"nmol/L"}}]}
{"resourceType":"SubstanceDefinition","id":"dc-yellow-10-al-lake","contained":[{"resourceType":"SubstanceDefinition","id":"comp-quinoline-6-sulfonate","classification":[{"coding":[{"system":"http://example.europa.eu/fhir/SubstanceType","code":"chemical","display":"Chemical"}]}],"name":[{"name":"Aluminum 2-(1,3-dioxo-2,3-dihydro-1H-inden-2-yl)quinoline-6-sulfonate","preferred":true}]},{"resourceType":"SubstanceDefinition","id":"comp-quinoline-8-sulfonate","classification":[{"coding":[{"system":"http://example.europa.eu/fhir/SubstanceType","code":"chemical","display":"Chemical"}]}],"name":[{"name":"Aluminum 2-(1,3-dioxo-2,3-dihydro-1H-inden-2-yl)quinoline-8-sulfonate","preferred":true}]},{"resourceType":"SubstanceDefinition","id":"comp-substrate","classification":[{"coding":[{"system":"http://example.europa.eu/fhir/SubstanceType","code":"chemical","display":"Chemical"}]}],"name":[{"name":"Unspecified aluminum substrate","preferred":true}],"description":"The aluminum substrate onto which the dye is precipitated to form the lake. Unspecified in GSRS."}],"identifier":[{"system":"http://fdasis.nlm.nih.gov","value":"CQ3XH3DET6"}],"status":{"coding":[{"system":"http://hl7.org/fhir/publication-status","code":"active","display":"Active"}]},"classification":[{"coding":[{"system":"http://example.europa.eu/fhir/SubstanceType","code":"mixture","display":"Mixture"}]}],"domain":{"coding":[{"system":"http://example.europa.eu/fhir/Domain","code":"human","display":"Human use"}]},"description":"D\u0026C Yellow No. 10 Aluminum Lake — a pharmaceutical colorant produced by precipitating D\u0026C Yellow No. 10 (a mixture of the 6- and 8-sulfonate isomers of aluminum quinoline-2-yl-indanedione) onto an aluminum substrate. Used as an excipient (colourant) in solid oral dosage forms.","code":[{"code":{"coding":[{"system":"http://fdasis.nlm.nih.gov","code":"CQ3XH3DET6","display":"D\u0026C YELLOW NO. 10 ALUMINUM LAKE"}]}}],"name":[{"name":"D\u0026C Yellow No. 10 Aluminum Lake","preferred":true,"language":[{"coding":[{"system":"urn:ietf:bcp:47","code":"en","display":"English"}]}]}],"relationship":[{"substanceDefinitionReference":{"reference":"#comp-quinoline-6-sulfonate","display":"Aluminum quinoline-6-sulfonate isomer"},"type":{"coding":[{"system":"http://hl7.org/fhir/substance-relationship-type","code":"Component","display":"Component"}]}},{"substanceDefinitionReference":{"reference":"#comp-quinoline-8-sulfonate","display":"Aluminum quinoline-8-sulfonate isomer"},"type":{"coding":[{"system":"http://hl7.org/fhir/substance-relationship-type","code":"Component","display":"Component"}]}},{"substanceDefinitionReference":{"reference":"#comp-substrate","display":"Unspecified aluminum substrate"},"type":{"coding":[{"system":"http://hl7.org/fhir/substance-relationship-type","code":"Component","display":"Component"}]}}]}
{"resourceType":"SubstanceDefinition","id":"peg3350","identifier":[{"system":"http://example.europa.eu/fhir/SMSId","value":"PEG3350P"}],"status":{"coding":[{"system":"http://hl7.org/fhir/publication-status","code":"active","display":"Active"}]},"classification":[{"coding":[{"system":"http://example.europa.eu/fhir/SubstanceType","code":"polymer","display":"Polymer"}]}],"domain":{"coding":[{"system":"http://example.europa.eu/fhir/Domain","code":"human","display":"Human use"}]},"description":"Polyethylene Glycol 3350 (PEG 3350, Macrogol 3350) — a synthetic polyether of ethylene oxide with number-average molecular weight approximately 3350 Da. Linear homopolymer used as an osmotic laxative and a pharmaceutical excipient.","code":[{"code":{"coding":[{"system":"http://example.europa.eu/fhir/Substance","code":"PEG3350P"}]}}],"name":[{"name":"Polyethylene Glycol 3350","preferred":true,"language":[{"coding":[{"system":"urn:ietf:bcp:47","code":"en","display":"English"}]}],"official":[{"authority":{"coding":[{"system":"http://hl7.org/fhir/substance-name-authority","code":"USAN","display":"USAN"}]},"status":{"coding":[{"system":"http://hl7.org/fhir/publication-status","code":"active","display":"Active"}]}}]},{"name":"Macrogol 3350","preferred":false}],"molecularWeight":[{"type":{"coding":[{"system":"http://example.europa.eu/fhir/WeightType","code":"number-average","display":"Number average (Mn)"}]},"amount":{"value":3350,"unit":"g/mol","system":"http://unitsofmeasure.org","code":"g/mol"}}],"polymer":{"class":{"coding":[{"system":"http://hl7.org/fhir/polymer-class","code":"homopolymer","display":"Homopolymer"}]},"geometry":{"coding":[{"system":"http://hl7.org/fhir/polymer-geometry","code":"linear","display":"Linear"}]},"monomerSet":[{"ratioType":{"coding":[{"system":"http://hl7.org/fhir/polymer-monomer-ratio-type","code":"monomer-polymer-ratio","display":"Monomer/Polymer ratio"}]},"startingMaterial":[{"code":{"concept":{"coding":[{"system":"http://example.europa.eu/fhir/Substance","code":"ethylene-oxide","display":"Ethylene oxide"}]}},"category":{"coding":[{"system":"http://hl7.org/fhir/polymer-starting-material-category","code":"chemical-substance","display":"Chemical substance"}]},"isDefining":true,"amount":{"value":76,"unit":"monomers per polymer"}}]}],"repeat":[{"averageMolecularFormula":"(C2H4O)76","repeatUnitAmountType":{"coding":[{"system":"http://hl7.org/fhir/polymer-monomer-ratio-type","code":"sru-polymer-ratio","display":"SRU/Polymer ratio"}]},"repeatUnit":[{"unit":"-CH2-CH2-O-","orientation":{"coding":[{"system":"http://hl7.org/fhir/polymerisation-orientation","code":"head-tail","display":"Head-to-tail"}]},"amount":76,"degreeOfPolymerisation":[{"type":{"coding":[{"system":"http://hl7.org/fhir/degree-of-polymerisation-type","code":"number-average","display":"Number average"}]},"average":76,"low":70,"high":82}]}]}]}}
{"resourceType":"SubstanceDefinition","id":"her2","identifier":[{"system":"https://www.uniprot.org","value":"P04626"}],"status":{"coding":[{"system":"http://hl7.org/fhir/publication-status","code":"active","display":"Active"}]},"classification":[{"coding":[{"system":"http://example.europa.eu/fhir/SubstanceType","code":"protein","display":"Protein"}]}],"domain":{"coding":[{"system":"http://example.europa.eu/fhir/Domain","code":"human","display":"Human use"}]},"description":"Human HER2 (ErbB2, receptor tyrosine-protein kinase erbB-2). A transmembrane receptor of the EGFR family, frequently overexpressed in breast and gastric cancers. The molecular target of trastuzumab and other HER2-directed therapies.","code":[{"code":{"coding":[{"system":"https://www.uniprot.org","code":"P04626","display":"ERBB2_HUMAN"}]}}],"name":[{"name":"Receptor tyrosine-protein kinase erbB-2","preferred":true,"language":[{"coding":[{"system":"urn:ietf:bcp:47","code":"en","display":"English"}]}]},{"name":"HER2","preferred":false},{"name":"ErbB-2","preferred":false},{"name":"CD340","preferred":false}],"protein":{"sequenceType":{"coding":[{"system":"http://hl7.org/fhir/substance-sequence-type","code":"complete","display":"Complete"}]},"numberOfSubunits":1,"subunit":[{"subunit":1,"length":1255}],"gene":[{"sequenceOrigin":{"coding":[{"system":"http://hl7.org/fhir/gene-sequence-origin","code":"human","display":"Human"}]},"gene":{"concept":{"coding":[{"system":"http://www.genenames.org","code":"ERBB2","display":"Erb-B2 receptor tyrosine kinase 2"}]}}}]}}
{"resourceType":"SubstanceDefinition","id":"dermatophagoides-farinae","identifier":[{"system":"http://example.europa.eu/fhir/SMSId","value":"DERMFAR1S"}],"status":{"coding":[{"system":"http://hl7.org/fhir/publication-status","code":"active","display":"Active"}]},"classification":[{"coding":[{"system":"http://example.europa.eu/fhir/SubstanceType","code":"structurally-diverse","display":"Structurally Diverse"}]}],"domain":{"coding":[{"system":"http://example.europa.eu/fhir/Domain","code":"human","display":"Human use"}]},"description":"Dermatophagoides farinae — American house dust mite allergen extract. A structurally diverse substance defined by its source organism rather than a discrete chemical structure, used in allergen immunotherapy products.","code":[{"code":{"coding":[{"system":"http://example.europa.eu/fhir/Substance","code":"DERMFAR1S"}]}}],"name":[{"name":"Dermatophagoides farinae","preferred":true,"language":[{"coding":[{"system":"urn:ietf:bcp:47","code":"en","display":"English"}]}],"official":[{"authority":{"coding":[{"system":"http://hl7.org/fhir/substance-name-authority","code":"USAN","display":"USAN"}]},"status":{"coding":[{"system":"http://hl7.org/fhir/publication-status","code":"active","display":"Active"}]}}]},{"name":"American house dust mite","preferred":false}],"sourceMaterial":{"type":{"coding":[{"system":"http://hl7.org/fhir/substance-source-material-type","code":"Animal","display":"Animal"}]},"genus":{"coding":[{"system":"http://example.europa.eu/fhir/Genus","code":"Dermatophagoides","display":"Dermatophagoides"}]},"species":{"coding":[{"system":"http://example.europa.eu/fhir/Species","code":"farinae","display":"D. farinae"}]},"part":{"coding":[{"system":"http://example.europa.eu/fhir/Part","code":"whole-organism","display":"Whole organism"}]}}}